Q BioMed Announces Updates on Commercialization of Non-Opioid Metastatic Cancer Pain Drug
New York, New York--(Newsfile Corp. - July 11, 2019) - Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, is pleased to announce the latest updates on its non-opioid therapy for the debilitating pain associated with metastatic skeletal cancer.We have been working hard to commercialize both our Strontium-89 products. In addition to the global exclusive license to generic Strontium-89 from BioNucleonics Inc. ("BNI"), we accelerated our global commercial launch by purchasing the...
2019-07-11 8:30 AM EDT
Q BioMed Files for Orphan Drug Designation with U.S. FDA for Autism Spectrum Disorder Subtype
New York, New York--(Newsfile Corp. - June 28, 2019) - Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today it has filed an application for Orphan Drug designation with the U.S. FDA's Office of Orphan Product Development for QBM-001, which is designed to treat pediatric minimally verbal autism (PVMA). Q BioMed anticipates commencing clinical...
2019-06-28 8:30 AM EDT
Q BioMed Responds to OTC Markets Request for Clarity on Promotional Activity
New York, New York--(Newsfile Corp. - June 24, 2019) - Q BioMed Inc. (OTCQB: QBIO), is providing this response at the request of the OTC markets inquiry into recent expanded investor awareness activities undertaken by the Company. As part of the company's effort to bring awareness to our development of several drug candidates to treat a variety of diseases and to highlight the assets in its drug portfolio, the Company's investor relations firm, Cayvan Consulting engaged a new sub-contracted...
2019-06-24 5:00 PM EDT
Q BioMed Advances QBM-001 for the Treatment of Autism Spectrum Disorder Subtype
U.S.Orphan Drug designation application to be filed in June 2019 based on Q BioMed's recent breakthrough discovery of disease biomarkersShort 12 month pivotal clinical trial to start as early as Q1 2020New York, New York--(Newsfile Corp. - June 4, 2019) - Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration company, today...
2019-06-04 8:30 AM EDT
Q BioMed Research Partner Mannin Research to Attend ARVO 2019 Annual Meeting
New York, New York--(Newsfile Corp. - April 24, 2019) - Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, announced today its technology partner Mannin Research will be attending ARVO 2019 the Annual Meeting of the Association for Research in Vision and Ophthalmology from April 28 to May 2, 2019. ARVO is the largest and most respected eye and vision research organization in the world. This year's annual meeting will be held at the Vancouver Convention Center in Vancouver,...
2019-04-24 8:00 AM EDT
In a Major Breakthrough, Q BioMed Discovers First Biomarkers for Pediatric Nonverbal Autism Subgroup
York, New York--(Newsfile Corp. - April 10,...
2019-04-10 8:30 AM EDT
Q BioMed and Mannin Research to Develop GDF15 Biomarker Glaucoma Diagnostic Kit Through Collaboration with McMaster University
Enabling technology to more effectively manage glaucoma progression and patient treatmentServes unmet need - Currently no single examination or diagnostic test is able to accurately predict disease progressionSimple diagnostic test that can be performed at a physician's office with no external expensive equipmentNew York, New York--(Newsfile Corp. - March 19, 2019) - Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration development company, announced today that its...
2019-03-19 7:00 AM EDT
Q BioMed Licenses Novel Biomarker for Monitoring Glaucoma Severity and Progression from Washington University
New York, New York--(Newsfile Corp. - March 11, 2019) - Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration development company, is pleased to announce it has exercised its option to exclusively license GDF15, a diagnostic marker for determining the severity of glaucoma using the expression levels of Growth Differentiation Factor 15 (GDF15) from the Washington University in St. Louis. Determining the severity of glaucoma using this biomarker will aid in treatment...
2019-03-11 8:30 AM EDT
Q BioMed's Autism Spectrum Disorder Drug Development Program Featured in February Issue of Leading Pharma/Biotech Newspaper
New York, New York--(Newsfile Corp. - February 26, 2019) - Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, today announced that in the February issue of DDNews, journalists conducted an interview with Q BioMed CEO Dennis Corin, focused on the mechanism of action, development path, and market opportunities of QBM-001 which is being developed to help treat rare pediatric non-verbal autism spectrum disorder. The article is available at the following link on page 21 and 23:...
2019-02-26 8:00 AM EST
Interviews with CEO Denis Corin of Q BioMed and CEO George Nikopoulos of Mannin Research
New York, New York--(Newsfile Corp. - February 22, 2019) - Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, announces multiple interviews with the company's CEO, Denis Corin, and the Q BioMed team are now available.An exclusive video interview with Chairman and CEO Denis Corin from the NASDAQ MarketSite. Mr. Corin discusses Q BioMed developments and updates and the upcoming catalyst for 2019. Please click here to watch the full interview.Denis Corin joins Olivia Voznenko...
2019-02-22 8:00 AM EST